Tirzepatide

DRAGON PHARMA TIRZEPATIDE

Tirzepatide is a novel pharmaceutical agent designed to address metabolic disorders, particularly diabetes. It belongs to the class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

DRUG COMPOSITION

Tirzepatide is composed of a synthetic peptide designed to activate both GIP and GLP-1 receptors, promoting glucose-dependent insulin secretion.

LAB TEST REPORT

PHARMACEUTICAL FORM

Tirzepatide is typically formulated as a freeze-dried powder, or solution for injection, allowing for subcutaneous administration.

PHARMACEUTICAL GROUP AND ATC CODE

Pharmaceutical group: Incretin mimetics. ATC code: A10BJ03.

PHARMACOLOGICAL PROPERTIES

Tirzepatide stimulates both GIP and GLP-1 receptors, leading to enhanced insulin secretion, reduced glucagon release, delayed gastric emptying, and increased satiety. These effects collectively contribute to improved glucose control.

PROFILE

• Chemical name: Tirzepatide
• Chemical formula: Not publicly disclosed (proprietary information)
• Percentage of anabolic activity: Not applicable (not an anabolic steroid)
• Percentage of androgenic activity: Not applicable
• Active half life: Approximately 5 days
• Recommended dosage: Individualized; consult a healthcare professional
• Acne: Not a known side effect
• Bloating (water retention): Not a known side effect
• HBR: Not applicable
• Hepatic toxicity: Not a known side effect
• Aromatization: Not applicable

THERAPEUTICAL INDICATIONS

Tirzepatide is indicated for the management of type 2 diabetes mellitus in adults, aiming to achieve glycemic control and reduce the risk of cardiovascular events.

DOSES AND METHOD OF ADMINISTRATION

Dosage and administration of tirzepatide depend on individual patient needs and response. It is typically administered subcutaneously once a week.

CYCLE/STACKING

Tirzepatide is not typically cycled like performance-enhancing substances. It is intended for continuous use as part of a diabetes management plan.

POST CYCLE THERAPY

Post cycle therapy is not applicable for tirzepatide, as it is a medication for a chronic condition and not used in the context of performance enhancement.

SIDE EFFECTS

Common side effects may include nausea, vomiting, diarrhea, and injection site reactions. Serious side effects are rare but may include pancreatitis and hypoglycemia.

CONTRAINDICATIONS

Tirzepatide is contraindicated in individuals with a history of severe gastrointestinal disease, multiple endocrine neoplasia syndrome type 2, or hypersensitivity to the drug.

OVERDOSE

There is limited information on overdose, and any suspected overdose should be promptly addressed with medical attention.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Tirzepatide carries warnings for potential risks, including pancreatitis, hypoglycemia, renal impairment, and medullary thyroid carcinoma. Careful patient monitoring is advised.

INTERACTIONS WITH OTHER DRUGS

Tirzepatide may interact with other medications, and healthcare providers should be informed of all drugs taken by the patient.

PRESENTATION, PACKAGING

Freeze-dried powder, in 2 mL vials.

STORAGE

Tirzepatide should be stored according to the manufacturer's instructions, typically in a refrigerator.

DELIVERY TO THE USA

Tirzepatide is available for secure and discreet delivery to the USA through authorized supplier - Steroid.biz.

LEGAL STATUS

Tirzepatide is a prescription medication and should be used only under the supervision of a qualified healthcare professional.

LAB TEST RESULTS

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma
Europe

EXTERNAL LINKS

• Tirzepatide Wiki, wikipedia.org
• Tirzepatide: Uses, Dosage, Side Effects & Warnings, drugs.com
• An Introduction to Tirzepatide, diabetesjournals.org.